Abstract

Night shift work impairs vigilance performance, reduces the ability to stay awake, and compromises brain health. To investigate if the magnitude of these adverse night shift work effects differs between sexes and weight groups, 47 men and women with either normal weight or obesity participated in one night of sleep and one night of total sleep loss. During the night of sleep loss, participants’ subjective sleepiness, vigilance performance, and ability to stay awake during 2-min quiet wake with eyes closed were repeatedly assessed. In addition, blood was collected in the morning after sleep loss and sleep to measure central nervous system (CNS) health biomarkers. Our analysis showed that women were sleepier during the night of sleep loss (P < 0.05) and spent more time in microsleep during quiet wake testing (P < 0.05). Finally, higher blood levels of neurofilament light chain, a biomarker of axonal damage, were found among women in the morning after sleep loss (P < 0.002). Compared with normal-weight subjects, those with obesity were more prone to fall asleep during quiet wake (P < 0.05) and exhibited higher blood levels of the CNS health biomarker pTau181 following sleep loss (P = 0.001). Finally, no differences in vigilance performance were noted between the sex and weight groups. Our findings suggest that the ability to stay awake during and the CNS health biomarker response to night shift work may differ between sexes and weight groups. Follow-up studies must confirm our findings under more long-term night shift work conditions.

Details

Title
Acute sleep loss increases CNS health biomarkers and compromises the ability to stay awake in a sex-and weight-specific manner
Author
van Egmond, Lieve T. 1   VIAFID ORCID Logo  ; Bukhari, Shervin 2   VIAFID ORCID Logo  ; Benedet, Andrea Lessa 3 ; Ashton, Nicholas J. 3 ; Meth, Elisa M. S. 2 ; Boukas, Alexander 2 ; Engström, Joachim 2 ; Ilemosoglou, Maria 2 ; Blennow, Kaj 3   VIAFID ORCID Logo  ; Zetterberg, Henrik 4   VIAFID ORCID Logo  ; Benedict, Christian 2   VIAFID ORCID Logo 

 Uppsala University, Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457); Uppsala University, Department of Pharmaceutical Biosciences, Molecular Neuropharmacology (Sleep Science Laboratory), Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457) 
 Uppsala University, Department of Pharmaceutical Biosciences, Molecular Neuropharmacology (Sleep Science Laboratory), Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457) 
 The Sahlgrenska Academy at the University of Gothenburg, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Mölndal, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); Sahlgrenska University Hospital, Clinical Neurochemistry Laboratory, Mölndal, Sweden (GRID:grid.1649.a) (ISNI:000000009445082X) 
 The Sahlgrenska Academy at the University of Gothenburg, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Mölndal, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); Sahlgrenska University Hospital, Clinical Neurochemistry Laboratory, Mölndal, Sweden (GRID:grid.1649.a) (ISNI:000000009445082X); UCL Institute of Neurology, Department of Neurodegenerative Disease, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201); Dementia Research Institute at UCL, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201); Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China (GRID:grid.24515.37) (ISNI:0000 0004 1937 1450) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
21583188
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2712352909
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.